Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10 International Symposium on Amyloid and Amyloidosis

Morie A. Gertz,* Ray Comenzo, Rodney H. Falk, Jean Paul Fermand, Bouke P. Hazenberg, Philip N. Hawkins, Giampaolo Merlini, Philippe Moreau, Pierre Ronco, Vaishali Sanchorawala, Orhan Sezer, Alan Solomon, and Giles Grateau Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota Hematology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York Amyloid Treatment and Research Program, Boston University, School of Medicine, Boston, Massachusetts Hôpital Saint-Louis, Paris, France Department of Rheumatology, University Hospital, Groningen, The Netherlands 6 The National Amyloidosis Center, Department of Medicine, Royal Free Hospital, London, England Amyloid Center, Biotechnology Research Laboratory, University Hospital, IRCCS Policlinico, San Mateo, Pavia, Italy Department of Hematology, University Hospital, Nantes, France 9 Inserm 489 Nephrology Service, Hospital Tenon, Paris, France Myeloma and Lymphoma Research Unit, Hospital Charite, Department of Hematology and Oncology, Humboldt University, Berlin, Germany Human Immunology and Cancer Program, University of Tennessee, Graduate School of Medicine, Knoxville, Tennessee 12 Public Assistance Hospital, Hôtel-Dieu, Paris, France